EUCTR2012-000598-22-DE进行中（未招募）1 期
Randomised, open-label phase II study to compare the safety and efficacy of lapatinib plus trastuzumab or lapatinib plus capecitabine in trastuzumab-resistant HER2-overexpressing metastatic breast cancer - THOR
Berufsverband der niedergelassenen gynäkologischen Onkologen in Deutschland e.V.; BNGO e.V.0 个研究点目标入组 100 人开始时间: 2013年2月15日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Women with histologically confirmed breast cancer; measurable metastatic disease; HER2-positive (IHC 3+ or ISH positive); Hormone receptor-negative; prior treatment with trastuzumab, anthracycline and taxanes; progression on trastuzumab as first-line or second-line therapy; no prior treatment with lapatinib within last 6 months; Adequate hematologic, renal and liver function; normal cardiac function with LVEF of =50%; ECOG performance status 0-1; No evidence of brain metastases (asymptomatic metastases that have been clinically stable for 3 months are allowed); no significant cardiovascular disease or other serious medical condition; written informed consent to participate in the trial and to the donation of formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer available for central testing.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with confirmed brain metastases or a history of primary central nervous system tumours or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Patients with treated brain metastases that are asymptomatic and have been clinically stable for 3 months will be eligible for protocol participation.
- •2. Hormone receptor-positive patients or prior treatment with lapatinib within the last 6 months
- •3. More than 2 line of trastuzumab-based treatment for advanced disease
- •4. Significant cardiovascular disease, such as
- •?History of myocardial infarction, acute coronary syndromes (including unstable angina), or history of coronary angioplasty/stenting/bypass grafting within past 6 months.
- •?History of symptomatic congestive heart failure (CHF) New York Heart Association (NYHA) Classes II-IV or LVEF <50% by either ECHO or MUGA
- •?Severe cardiac arrhythmia requiring medication or severe conduction abnormalities
- •?Poorly controlled hypertension (resting diastolic blood pressure >100 mmHg)
- •?Clinically significant valvular disease, cardiomegaly, ventricular hypertrophy, or cardiomyopathy
- •5. QTc prolongation defined as a QTc interval >460 msecs or other significant ECG abnormalities including 2nd degree (type II) or 3rd degree AV block or bradycardia (ventricular rate <50 beats/min)
- •6. Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- •7. Malabsorption syndrome or other condition that would interfere with enteral absorption
- •8. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator’s opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent.
- •9. Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol.
- •10. Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study entry.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatmentEUCTR2012-003330-16-DEGBG Forschungs GmbH (German Breast Group)
进行中（未招募）
1 期
Efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID-19 pneumoniaEUCTR2020-001413-20-ESFundació Clínic per a la Recerca Biomèdica100
进行中（未招募）
不适用
Randomized, open-label phase II study evaluating the safety and efficacy of Cetuximab plus modified FOLFOX - 6 versus modified FOLFOX - 6 alone as 2nd line therapy after progression on the 1st line treatment with Cetuximab + FOLFIRI in patients with metastatic colorectal cancer KRAS wild-type – TAGUS Study - TAGUS StudyEUCTR2008-008282-36-PTGrupo de Investigação do Cancro Digestivo
撤回
2 期
A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of PXL770 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy (AMN)AdrenoleukodystrophyNL-OMON51808Poxel S.A.14
进行中（未招募）
1 期
Trial on patients with adrenomyeloneuropathy to assess PXL770's behaviour, a new potential medicine, in the bodyEUCTR2021-006223-18-DEPoxel S.A.24